Rhamy Zeid
C4 Therapeutics (United States)(US)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Chromatin Remodeling and Cancer, Ubiquitin and proteasome pathways, Neuroblastoma Research and Treatments
Most-Cited Works
- → Melanoma genome sequencing reveals frequent PREX2 mutations(2012)761 cited
- → Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition(2013)628 cited
- → BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment(2017)473 cited
- → Active medulloblastoma enhancers reveal subgroup-specific cellular origins(2016)394 cited
- → BET Bromodomain Inhibition of MYC -Amplified Medulloblastoma(2013)346 cited
- → Transcription control by the ENL YEATS domain in acute leukaemia(2017)318 cited
- → MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism(2016)281 cited
- → Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma(2018)241 cited
- → Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer(2020)199 cited
- → Proinvasion Metastasis Drivers in Early-Stage Melanoma Are Oncogenes(2011)138 cited